Alliance A011801 (compassHER2 RD): postneoadjuvant T-DM1 + tucatinib/placebo in patients with residual HER2-positive invasive breast cancer (NCT04457596)
- Citation:
- J Clin Oncol vol 39 (suppl 15) TPS595
- Meeting Instance:
- ASCO 2021
- Year:
- 2021
- Type:
- Abstract
- Sub type:
- Poster General
- Funding:
- NCTN
- Endpoint:
- No-Endpoint
- Analysis:
- Trial-Description-Only
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- epreprint
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- No
- Parents:
- None
- Children:
- 3617
- Pharmas:
- Seagen
- Grants:
- U10CA180821, U10CA180882, U24CA196171
- Corr. Author:
- Authors:
- Ciara C. O'Sullivan Karla V. Ballman Linda McCall Tyler Zemla Anna Weiss Melissa Mitchell Victoria Blinder Nadine M. Tung William J. Irvin Myounghee Lee Matthew P. Goetz W. Fraser Symmans Virginia F. Borges Ian Krop Ann H. Partridge Lisa A. Carey
- Networks:
- LAPS-CO070, LAPS-CT018, LAPS-MA036, LAPS-MN026, LAPS-NC007, LAPS-NY016, LAPS-TX035, MD015, NY167, SCOR
- Study
- Alliance-A011801
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 3
- Keywords: